Abbott Q1 Report 2023

“Our first-quarter results reflect a very strong start to the year,” said Robert B. Ford, chairman and chief executive officer, Abbott. “Growth in our underlying base businesses accelerated, including particularly strong results in Medical Devices, Established Pharmaceuticals and Nutrition.”

Abbott Financial Results

• First-quarter GAAP diluted EPS of $0.75 and adjusted diluted EPS of $1.03, which excludes specified items.
• Projected full-year 2023 diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 remains unchanged.
• Projected full-year adjusted EPS from continuing operations of $4.30 to $4.50 remains unchanged and now reflects an increased outlook for the underlying base business offset by a lower forecasted earnings contribution from COVID-19 testing-related sales.
• Abbott now projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high single-digits2 and COVID-19 testing-related sales of approximately $1.5 billion.